Yes, Zoladex (goserelin acetate) can and should be administered concurrently with radiation therapy for appropriate prostate cancer patients.
For patients with Stage T2b-T4 (Stage B2-C) localized or high-risk prostate cancer, Zoladex is specifically indicated to be given in combination with radiation therapy, starting 8 weeks before radiotherapy and continuing during radiation treatment. 1
FDA-Approved Dosing Protocol
The FDA label for Zoladex provides two specific regimens when combining with radiation therapy 1:
Option 1 (Preferred for simplicity):
- ZOLADEX 3.6 mg depot given 8 weeks before radiotherapy
- Followed by ZOLADEX 10.8 mg depot at 28 days
- Continue through radiation
Option 2:
- Four injections of ZOLADEX 3.6 mg depot at 28-day intervals
- Two depots given before radiotherapy
- Two depots given during radiotherapy
Clinical Evidence Supporting Concurrent Use
The combination of Zoladex with radiation therapy is well-established and safe. Clinical trial data demonstrates that treatment with ZOLADEX and flutamide did not add substantially to the toxicity of radiation treatment alone 1. The adverse events during acute radiation therapy (rectum/large bowel, bladder, skin reactions) were comparable between the combination therapy group and radiation-only group 1.
Guideline Recommendations
Current NCCN guidelines strongly support this approach. For high-risk localized prostate cancer, clinicians should offer 24-36 months of ADT (androgen deprivation therapy) as an adjunct to either external beam radiation therapy alone or EBRT combined with brachytherapy 2. The AUA/ASTRO/SUO guidelines similarly recommend this combination for high-risk disease 3.
Safety Profile
The most common adverse events with concurrent Zoladex and radiation include 1:
- Hot flashes (46%)
- Diarrhea (40%)
- Nausea (9%)
- Skin rash (8%)
These side effects are manageable and rarely severe enough to warrant treatment discontinuation. The combination therapy showed similar rates of radiation-related complications (cystitis, proctitis, rectal bleeding) compared to radiation alone 1.
Important Caveats
- Tumor flare phenomenon: Like other GnRH agonists, Zoladex initially causes transient testosterone increases before suppression. Monitor for temporary worsening of symptoms in the first few weeks 1
- Cardiovascular monitoring: Patients should be monitored for cardiovascular disease development, and QT interval prolongation should be considered in at-risk patients 1
- Injection site precautions: Extra care is needed in patients with low BMI or those on anticoagulation due to risk of injection site injury 1
Duration of Therapy
For high-risk localized prostate cancer treated with radiation, the standard duration is 24-36 months of ADT, not just during the radiation period 3. This extended duration has been shown to improve disease-free survival, local recurrence-free survival, and overall survival 4.
The concurrent use of Zoladex with radiation therapy is not only safe but represents standard-of-care for appropriate prostate cancer patients, with robust FDA approval and guideline support.